Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New $17 million Link Park will combine culture and productivity

Unique business park will be packed with amenities that focuses on investment in tenant, customer and employee happiness   August 4, 2015 (Kirkwood, N.Y.) – A new type of business park focused on employee satisfaction is making its way to the Southern Tier and will serve as the gateway to greater Binghamton business. Through the […]

Read More »

Heart effects of saturated fats may depend on overall diet

(Reuters Health) – While experts continue to debate the health effects of saturated fat, a new U.S. study suggests its link to heart disease depends on what else a person eats. Over time, cutting back on saturated fat was tied to a drop of up to 25 percent in heart disease risk – unless people […]

Read More »

Smart capsule to target colon diseases

A new electronic drug capsule engineered to deliver medications directly to the colon could potentially offer a more effective and cheaper option for treating people with gastrointestinal conditions, according to researchers at Purdue University in Indiana.   The device is comprised of two parts, one carrying a drug payload and the other housing electronics designed […]

Read More »

Walking while working may ease muscle pain

For many office workers, their job has literally become a pain in the neck. While standing desks are becomingly an increasingly popular option for those who suffer physical discomfort at work, a researcher at McGill University in Quebec says her study of treadmill workstations show them to be potentially more beneficial and able to help […]

Read More »

Israel’s MediWound signs $112 million deal in U.S. for burn treatment

Israel-based MediWound has signed a five-year, $112 million contract with the U.S. authority that handles public health medical emergencies to further develop and buy the company’s drug treatment for severe burns. Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research […]

Read More »

WHO ramps up HIV drug push with call for early treatment for all

Everyone with HIV should be given anti-retroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the World Health Organization (WHO) said on Wednesday.   Recent clinical trials have confirmed that early drug use extends the lives of those with the AIDS-causing virus and cuts the risk of […]

Read More »

Webinar on Improving Clinical Trial Performance – October 2015

Media Alert: Webinar on Improving Clinical Trial Performance – October 2015   WHAT: CRO Analytics will host an upcoming webinar in October, “QPIs: What They Are And How They Drive Your KPIs”. This webinar will review the key concepts surrounding clinical trial metrics malpractice, performance measurement, and Quality Performance Indicators (QPIs); all topics put forth […]

Read More »

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Astellas obtains worldwide commercial rights to Chromocell’s novel, peripherally restricted NaV1.7 antagonist, CC8464 Chromocell receives $15 million in upfront payments and is eligible to receive over $500 million in development and commercial milestones plus double digit royalties on sales; additional development initiated by Chromocell could result in additional payments and co-promotion rights in the U.S. […]

Read More »

U.S. biotech to apply artificial intelligence to UK genome study

Berg, a private company that uses artificial intelligence to discover new drugs and diagnostics, will help England’s national genomics project mine DNA and health data from thousands of British citizens for potential drug targets. Berg, based in Boston, was co-founded in 2006 by Silicon Valley real estate billionaire Carl Berg. Since then, it has been […]

Read More »

Drug industry must address image problem over prices: Teva executive

Teva Pharmaceutical Industries Ltd’s research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the United States.   Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom